<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>An update from TransThera Sciences (Nanjing). Inc. ( (HK:2617) ) is now available. TransThera Sciences (Nanjing) has reported new clinical data for its spectrum-selective multi-kinase inhibitor tinengotinib, targeting FGFR1-3, JAK1/2, VEGFRs and Aurora A/B, in patients with advanced solid tumors. The phase Ib/II study, conducted in China, evaluated tinengotinib both as a monotherapy and in combination with the immunotherapy agent atezolizumab. Tinengotinib achieved objective response rates of 16.7% as a standalone treatment and 22.6% when combined with atezolizumab, with particularly strong results in cholangiocarcinoma patients. The drug showed notable efficacy in cases with FGFR2 fusion that had progressed on prior FGFR inhibitors, and the combination regimen delivered meaningful disease control in patients previously treated with immune checkpoint inhibitors, supporting continued clinical development of the asset. More about TransThera Sciences (Nanjing). Inc. TransThera Sciences (Nanjing), Inc. is a China-based biopharmaceutical company focused on developing innovative targeted therapies for solid tumors. Listed in Hong Kong, the company is advancing a pipeline of kinase inhibitors and immunotherapy combinations aimed at difficult-to-treat cancers such as cholangiocarcinoma and other advanced solid tumors. Average Trading Volume: 2,500,535 Technical Sentiment Signal: Strong Sell Current Market Cap: HK$15B See more data about 2617 stock on TipRanks’ Stock Analysis page.</div>

159992

520500

512290

TransThera Sciences (Nanjing) has reported promising results for its multi-kinase inhibitor tinengotinib in advanced solid tumors. In a phase Ib/II study, tinengotinib achieved objective response rates of 16.7% as a monotherapy and 22.6% in combination with atezolizumab, particularly effective in cholangiocarcinoma patients. The drug demonstrated efficacy in FGFR2 fusion cases resistant to prior treatments, supporting further clinical development.

Tip Ranks

Yinhua CSI Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Guotai CSI Bio-medicine ETF

China Universal CNI HK Connect Innovative Drugs Industry ETF

E Fund Hang Seng SCHK Innovative Drug ETF

ChinaAMC CSI Biotechnology Theme ETF

ChinaAMC SSE Health Care ETF Initiating Fund

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

Minsheng Royal CSI Biotechnology Theme ETF

China Merchants CSI Biotechnology Theme ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

Fullgoal CSI Hugangshen Innovative Drugs Industry ETF

E Fund CSI 300 Health Care ETF

Hwabao WP CSI Pharmaceuticals ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Penghua CSI HK Connect Health Care Composite ETF

E Fund CSI Biotechnology Theme ETF

Bosera Hang Seng Health Care ETF(QDII)

TRANSTHERA-B

TransThera reports promising tinengotinib results in advanced solid tumors